Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB1275 Monotherapy and Combinations in Advanced Solid Tumors
NCT04060342Phase 1Terminated
- Sponsor
- Gossamer Bio
- Start
- Aug 2019
- Primary completion
- Apr 2022
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 1, open-label trial of gb1275 in pancreatic adenocarcinoma (PDAC), esophageal adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) and 11 more (6 arms), sponsored by Gossamer Bio. Primary endpoints: Incidence of Dose Limiting Toxicities, Incidence of Adverse Events and 3 more. Started Aug 2019; status: terminated.
02
Drugs
gb1275
03
Conditions
pancreatic adenocarcinoma (PDAC)esophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04060342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060342.